Blog
Latest articles, insights, and updates from the blog.
Have a question about this topic?
Use the contact page when you need to send feedback, request a correction, or ask about the resource.
Trump's Psychedelic EO: What It Means for Ketamine Patients
President Trump's 2026 executive order on psychedelic research signals new federal support for ketamine therapy. Here's what online patients need to know.
What Ketamine's Side Effect Data Means for You
New clinical guidance on NMDA antagonist side effects and discontinuation rates has direct implications for patients pursuing ketamine therapy online.
What New NMDA Data Means for Your Ketamine Care
New clinical guidance on ketamine and esketamine side effect tracking is reshaping how providers manage treatment-resistant depression. Here's what it means for you.
Glutamate Treatments Reshape TRD Care in 2026
New research confirms glutamate-based treatments like esketamine offer fast relief for treatment-resistant depression. Here's what it means for online ketamine care.
New Research on Ketamine Side Effects and What It Means
New clinical data on NMDA antagonist side effects and discontinuation rates reveals what telehealth ketamine patients should expect from accountable providers.
AI Prescribing Psych Meds: What It Means for Ketamine Care
A Utah AI prescribing pilot raises safety questions. Here's what it means for ketamine telehealth patients seeking safe, supervised online treatment.
How Doctors Choose TRD Treatments in 2026
New guidance on TRD treatment selection highlights ketamine's role alongside esketamine and brain stimulation. What patients need to know before choosing care.
Esketamine's Role in Treatment-Resistant Depression Care
New clinical insights on esketamine for treatment-resistant depression reveal how providers choose care and what barriers patients face in 2026.
New PTSD Prevention Drug Trial: What It Means for Patients
A new DoD-backed Phase 2a trial tests BXCL501 for acute stress reactions. Here's what it means for ketamine patients seeking PTSD treatment in 2026.
Why 'Good Enough' Depression Care Is No Longer Enough
New clinical guidance pushes for true remission in treatment-resistant depression. Here's what that means for patients exploring ketamine therapy.
BPL-003 Trial Results: What They Mean for TRD Patients
New phase 2a data on BPL-003 shows lasting depression symptom reduction. Here's what it means for patients exploring ketamine and emerging TRD therapies.
New PTSD Prevention Drug Trial: What Patients Should Know
A new DoD-backed trial is testing BXCL501 for acute stress reactions. Here's what it means for ketamine patients pursuing PTSD treatment today.